Table 5.
Identified germs and medical treatment
| Year | Positive cultures | Identified germs | Antibiotic treatment | Mean duration of treatment | Other medical treatment* |
|---|---|---|---|---|---|
| 2017 | 17 (56%) | S. anginosus (6), S. intermedius (4), S. pneumoniae (2), S. pyogenes (1), Strept. group F (1), F. necrophorum (2), S. epidermidis (1), S. aureus (1) | 29 (97%) |
> 10 weeks in 8 cases (27%) Mean duration in the remaining cases: 5.6 weeks |
16 (53%) |
| 2018 | 21 (70%) | S. intermedius (5), S. anginosus (3), S. pyogenes (1), S. milleri (2), S. pneumoniae (1), S. epidermidis (4), S. constellatus (1), H. influenzae (1), H. haemolyticus (1), P. aeruginosa (1), N. macacae (1), P. loescheii (1), F. necrophorum (2), F. nucleatum (1) | 30 (100%) | 6.4 weeks | 13 (43%) |
| 2019 | 18 (72%) | S. intermedius (3), S. anginosus (1), S. pyogenes (4), P. anaerobius (2), S. epidermidis (1), S. constellatus (1), S. aureus (1), P. aeruginosa (1), F. necrophorum (3), E. faecalis (1), P. acnes (1), Bacteroides spp. (2), Actinomyces spp. (1) | 24 (96%) |
> 10 weeks in 3 cases (12%) Mean duration in the remaining cases: 4.9 weeks |
12 (48%) |
| 2020 | 15 (88%) | S. intermedius (7), S. constellatus (1), H. influenzae (2), S. aureus (2), S. epidermidis (2), F. nucleatum (1), E. corrodens (1), M. tuberculosis (1), C. albicans (1) | 17 (100%) |
> 10 weeks in 3 cases (17%) Mean duration in the remaining cases: 6.7 weeks |
11 (64%) |
| 2021 | 16 (70%) | S. intermedius (5), S. constellatus (3), S. pneumoniae (3), S. anginosus (1), Strept. group F (1), H. influenzae (1), S. aureus (1), P. micra (1), E. cloacae (1), A. xylosoxidans (1) | 23 (100%) |
> 10 weeks in 6 cases (26%) Mean duration in the remaining cases: 6.0 weeks |
13 (56%) |
| 2022 | 42 (72%) | S. intermedius (17), S. pneumoniae (4), S. anginosus (7), S. constellatus (4), S. milleri (1), P. anaerobius (1), S. mitis (1), M. catarrhalis (1), S. aureus (3), H. influenzae (2), F. necrophorum (2), F. nucleatum (1), S. exiquia (1), S. moorei (1), D. pneumosintes (1), E. corrodens (4), C. albicans (1), P. micra (1), P. oralis (1), P. loescheii (1), A. europeus (1) | 58 (100%) |
> 10 weeks in 12 cases (20%) Mean duration in the remaining cases: 6.1 weeks |
35 (60%) |
| 2023 | 47 (66%) | S. intermedius (16), S. anginosus (8), S. tonsillaris (1), S. pneumoniae (3), S. pyogenes (8), S. mitis (1), Strept. group F (2), S. constellatus (1), C, singulare (1), S. lugdunensis (1), S. aureus 3), S. epidermidis (1), F. necrophorum (1), P. oralis (1), P. loescheii (1), Coccobacilli ssp. (1), Veillonella spp. (1), E. coli (1), H. influenzae (1), A. niger (1), A. fumigatus (1) | 71 (100% |
> 10 weeks in 5 cases (7%) Mean duration in the remaining cases: 5.5 weeks |
42 (59%) |
| Overall | 176 (69%) | / | 252 (99%) |
> 10 weeks: 37 cases (14%) Mean duration: 5.8 weeks |
142 (56%) |
*Steroids and/or anti-inflammatory drugs